ncRNA name
hsa-miR-185-3p
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Not available
Cancer name
Lung Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Erlotinib
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Up
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
These findings revealed a novel mechanism in which downregulation of miR-185-3p may induce overexpression of PFKL and MET and confer ER resistance in lung cells
Tissue resource
normal and tumor tissues of ER-resistant and ER-sensitive lung cancer
human lung cancer cell lines H1299
human lung cancer cell lines A549
Experiment
None
Institute
Nanjing Medical Hospital
Procell
Country
China
China
Continent
Asia
Asia